164 related articles for article (PubMed ID: 34647738)
1. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Petzer JP; Beteck RM
Bioorg Med Chem; 2020 Jun; 28(11):115468. PubMed ID: 32284225
[TBL] [Abstract][Full Text] [Related]
4. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies.
Wang X; Liu X; Huang J; Liu C; Li H; Wang C; Hong Q; Lei Y; Xia J; Yu Z; Dong R; Xu J; Tu Z; Duan C; Li S; Lu T; Tang W; Chen Y
Eur J Med Chem; 2022 Aug; 238():114461. PubMed ID: 35605362
[TBL] [Abstract][Full Text] [Related]
6. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
7. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 7-azaindoles as PDK1 inhibitors.
Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
[TBL] [Abstract][Full Text] [Related]
10. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
13. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
Yan L; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
[TBL] [Abstract][Full Text] [Related]
15. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
[TBL] [Abstract][Full Text] [Related]
17. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
[TBL] [Abstract][Full Text] [Related]
19. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.
Németh G; Greff Z; Sipos A; Varga Z; Székely R; Sebestyén M; Jászay Z; Béni S; Nemes Z; Pirat JL; Volle JN; Virieux D; Gyuris Á; Kelemenics K; Ay E; Minarovits J; Szathmary S; Kéri G; Orfi L
J Med Chem; 2014 May; 57(10):3939-65. PubMed ID: 24742150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]